WAY 174231
Alternative Names: beta-3-Adrenoceptor agonists research programme - Wyeth; Research programme: beta-3 adrenoceptor agonists - WyethLatest Information Update: 12 Oct 2011
At a glance
- Originator Wyeth
- Class
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 13 Aug 2003 No development reported - Preclinical for Obesity in USA (unspecified route)
- 13 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 16 Nov 2001 WAY 174231 has been chosen for further biological evaluations